205 related articles for article (PubMed ID: 8501501)
1. Cell kinetics as a predictive factor in node-positive breast cancer treated with adjuvant hormone therapy.
Silvestrini R; Daidone MG; Mastore M; Di Fronzo G; Coradini D; Boracchi P; Squicciarini P; Salvadori B; Veronesi U
J Clin Oncol; 1993 Jun; 11(6):1150-5. PubMed ID: 8501501
[TBL] [Abstract][Full Text] [Related]
2. 3H-thymidine-labeling index as a prognostic indicator in node-positive breast cancer.
Silvestrini R; Daidone MG; Valagussa P; Di Fronzo G; Mezzanotte G; Mariani L; Bonadonna G
J Clin Oncol; 1990 Aug; 8(8):1321-6. PubMed ID: 2380758
[TBL] [Abstract][Full Text] [Related]
3. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
[TBL] [Abstract][Full Text] [Related]
5. p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients.
Silvestrini R; Benini E; Veneroni S; Daidone MG; Tomasic G; Squicciarini P; Salvadori B
J Clin Oncol; 1996 May; 14(5):1604-10. PubMed ID: 8622078
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of proliferative activity and ploidy in node-negative breast cancers.
Silvestrini R; Daidone MG; Del Bino G; Mastore M; Luisi A; Di Fronzo G; Boracchi P
Ann Oncol; 1993 Mar; 4(3):213-9. PubMed ID: 8471553
[TBL] [Abstract][Full Text] [Related]
7. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
8. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
9. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes.
Fisher B; Dignam J; Tan-Chiu E; Anderson S; Fisher ER; Wittliff JL; Wolmark N
J Natl Cancer Inst; 2001 Jan; 93(2):112-20. PubMed ID: 11208880
[TBL] [Abstract][Full Text] [Related]
10. Tumor-proliferative activity, progesterone receptor status, estrogen receptor level, and clinical outcome of estrogen receptor-positive advanced breast cancer.
Paradiso A; Tommasi S; Mangia A; Lorusso V; Simone G; De Lena M
Cancer Res; 1990 May; 50(10):2958-62. PubMed ID: 2334898
[TBL] [Abstract][Full Text] [Related]
11. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
Voogd AC; Crommelin MA; Repelaer van Driel OJ; Tutein Nolthenius-Puylaert MC; Vreugdenhil G; Coebergh JW
Ned Tijdschr Geneeskd; 1998 Aug; 142(31):1772-8. PubMed ID: 9856143
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients.
Gasparini G; Toi M; Verderio P; Ranieri G; Dante S; Bonoldi E; Boracchi P; Fanelli M; Tominaga T
Int J Oncol; 1998 May; 12(5):1117-25. PubMed ID: 9538138
[TBL] [Abstract][Full Text] [Related]
13. Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients.
Gasparini G; Fox SB; Verderio P; Bonoldi E; Bevilacqua P; Boracchi P; Dante S; Marubini E; Harris AL
Clin Cancer Res; 1996 Jul; 2(7):1191-8. PubMed ID: 9816287
[TBL] [Abstract][Full Text] [Related]
14. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
Nordenskjöld A; Fohlin H; Fornander T; Löfdahl B; Skoog L; Stål O
Breast Cancer Res Treat; 2016 Nov; 160(2):313-322. PubMed ID: 27722840
[TBL] [Abstract][Full Text] [Related]
15. Biologic and clinicopathologic factors as indicators of specific relapse types in node-negative breast cancer.
Silvestrini R; Daidone MG; Luisi A; Boracchi P; Mezzetti M; Di Fronzo G; Andreola S; Salvadori B; Veronesi U
J Clin Oncol; 1995 Mar; 13(3):697-704. PubMed ID: 7884430
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
[TBL] [Abstract][Full Text] [Related]
19. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
[TBL] [Abstract][Full Text] [Related]
20. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
